Logo

IASO Biotherapeutics Reports the NMPA’s Acceptance of IND Application for Equecabtagene Autoleucel to Treat Neuromyelitis Optica Spectrum Disorder

Share this

IASO Biotherapeutics Reports the NMPA’s Acceptance of IND Application for Equecabtagene Autoleucel to Treat Neuromyelitis Optica Spectrum Disorder

Shots:

  • The NMPA has accepted the IND application of equecabtagene autoleucel for NMOSD. The application was based on ITT to evaluate the safety, tolerability, preliminary efficacy, PK, & PD of equecabtagene autoleucel in patients with refractory NMOSD
  • As of the cut-off date of Mar 2022, 12 patients received equecabtagene autoleucel cell reinfusion including 3 in 0.5×106 CAR-T cells/kg dose, 3 in 1.0×106 CAR-T cells/kg dose in the dose-escalation stage & 6 in expansion stage
  • In preliminary results, all patients experienced 1~2 CRS with no ICANS events, reduction in EDSS scores with improved visual acuity in 50% of patients, improved walking ability (67%) & bladder function (75%). The product is expected to be available to NMOSD patients shortly in China globally

Ref: IASO Biotherapeutics | Image: IASO Biotherapeutics

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions